PD-1/PD-L1 Cancer Immunotherapeutics Reshape Tumor Microenvironment - Clinical Evidence and Molecular Mechanisms for...

Area of Science:

• Immunology
• Oncology
• Biochemistry

Background:

• The PD-1/PD-L1 pathway on T cells and cancer cells suppresses anti-tumor immunity.
• Existing reviews focus on PD-1/PD-L1 in therapy resistance and adverse events, overlooking efficacy enhancement strategies.

Purpose of the Study:

• To provide a holistic view of PD-1/PD-L1 targeting by analyzing clinical trials, molecular mechanisms, ubiquitin-mediated PTMs, and gut microbiome crosstalk.
• To identify underappreciated modes for enhancing therapeutic efficacy in cancer treatment.
• To advocate for integrating precision medicine with AI for improved cancer therapies.

Main Methods:

• Comprehensive analysis of recent clinical trials involving immune checkpoint inhibitors (ICIs) targeting PD-1/PD-L1.
• Review of molecular mechanisms governing immune surveillance and the tumor microenvironment (TME).
• Examination of ubiquitin-mediated post-translational modifications (PTMs) and their role in the PD-1/PD-L1 axis.
• Exploration of gut microbiome interactions influencing the TME and PD-1/PD-L1 signaling.

Main Results:

• Underappreciated factors like PTMs and gut microbiome crosstalk significantly influence the PD-1/PD-L1 axis and TME.
• Integration of diverse factors provides novel insights into optimizing PD-1/PD-L1 targeted therapies.
• AI-driven analytics show promise in accelerating the discovery of effective ICIs and combination strategies.

Conclusions:

• Understanding the multifaceted roles of PTMs and the gut microbiome is crucial for enhancing PD-1/PD-L1 targeted cancer therapy.
• Integrating AI with precision medicine can revolutionize the development of novel immunotherapies.
• This review bridges translational research and clinical application by offering a holistic perspective on PD-1/PD-L1 modulation for improved cancer patient outcomes.